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Summary.-Of 100 children and adolescents with lymphoblastic leukaemia (ALL)
seen over a 6-year period, 25 developed clinically evident infiltration of the central
nervous system (CNS), despite early treatment with cranial radiotherapy and intra-
thecal methotrexate.
Nine of these 25 had the features of T ALL, though there were only 17 such patients
overall. Not only did those with T ALL get CNS disease more frequently, but they
did so much sooner after diagnosis (P<0001) and more commonly had associated
facial palsies (P<0.05). The tendency to develop CNS infiltration appeared to be
significantly related to the possession of T-cell markers (P<0-02), but not to the
diagnostic white cell count (P=0.37). These findings suggest that current CNS
prophylactic therapy is ineffective in most patients with T ALL.
IT HAS BEEN recognized for some time
that the T-cell variety of lymphoblastic
leukaemia (T ALL) carries a worse prog-
nosis than non-T disease (Tsukimoto et al.,
1976; Reid et al., 1977) and it has also been
suggested to be frequently associated with
meningeal (CNS) infiltration (Catovsky
et al., 1974; Sallan et al., 1980). However,
the inextricable association between T
ALL and high white counts, a well known
adverse prognostic feature in any ALL,
begs the question whether it is the cellular
characteristics ofT lymphoblasts or merely
their numbers that possibly predispose
them to infiltrate the CNS. We have
attempted to answer this by studying an
unselected group of ALL patients who
happened to have a particularly high
incidence of CNS involvement, and who
also included a relatively large number of
those with T-cell disease.
PATIENTS ANI) METHOD)S
The patients were all aged less than 18 ancl
came untreated to Sheffield hospitals over a
period of 6 years to April 1980. All such
patients with ALL were studied and the
diagnosis ANas based on accepted clinical,
morphological and cytochemical grounds,
with the addition, since 1975, of serologically
defined membrane markers. T-cell disease
was recognized on the basis of the blast cells'
ability to form rosettes wsith sheep erythro-
cytes and, in one case -where this could not be
tested, on the basis of the presence of a large
upper mediastinal mass together with strong
focal blast-cell acid phosphatase activity as
described by Catovsky et al. (1978).
All patients were treated with the current
Medical Research Couincil therapeutic trial,
UKALL III to VII inclusive, and all received
standard megavoltage cranial irradiation
(18-24 Gy) together with at least 5 doses of
intrathecal methotrexate within 8 to 10
-weeks ofstarting treatment. Systemic therapy
included, in all cases, vincristine, predniso-
lone, L-asparaginase, methotrexate and mer-
captopurine, with the addition, in some ofthe
putative high-risk patients (including the
T-cell cases) ofcyclophosphamide, cytarabine
and (a few) Adriamycin.
CNS involveinent was defined as the pie-
sence of headaches, nausea, vomiting, som01-
nolence, hlyperphagia, pathological wN-eiglht
gain, papilloedemna or cranial-nerve palsies
associated with more than 0 01 x 109/1 morplh-
ologically unequivocal blast cells in the
cerebrospinal fluid (CSF). Tro cases Mwith
unilateral VIi nerve palsy were inielud(ledT ALL AND THE CNS
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FIG.- Comparison of CNS remission in patients with non-T ALL (A, n= 83) and patients with T ALL
(B, n= 17). P < 0 001 (Logrank).
without definite blasts in the CSF (one T and
one non-T) as both subsequently developed
overt meningeal infiltration.
The time to CNS relapse was measured as
being from diagnosis to the first demonstra-
tion of CSF blasts or, in the two cases men-
tioned above, the onset of facial paralysis.
Statistical methods included x2 analysis (of
the frequency ofVIIth nerve palsy and hypo-
thalamic infiltration), Student's t test (for the
difference in mean times to CNS relapse ofthe
T and non-T patients with CNS disease), life
tables and logrank tests (of the frequency of
CNS relapse and time to that event in all the
T and non-T patients) and a multidimensional
contingency table as described by Shaffer
(1973) to assess the interdependence of T-cell
markers, CNS disease and diagnostic white
cell count (WCC).
RESULTS
One hundred patients with ALL pre-
sented during the study period including
17 (17%) with the features of T-cell
disease. Twenty-five developed CNS in-
volvement at some stage of their illness,
of whom 9 (36%) had T-cell disease. The
frequency of CNS relapse was much
greater and also the time to that event
much shorter in the T ALL patients when
they were compared to the non-Ts
(P < 0-001, see Figure).
Of the 16 patients with non-T ALL who
developed CNS disease, 4 had an asso-
ciated unilateral facial palsy and 5 pre-
sented as the hypothalamic syndrome
described by Greydanus et al. (1978). Of
the 9 T ALLs, however, 6 had an asso-
ciated facial palsy and none had the hypo-
thalamic syndrome. Thus, facial palsy is
commoner (P < 0.05) and hypothalamic
infiltration perhaps less common (0-1 <P
> 0.05) in T compared to non-T ALL (see
Table).
There was no significant difference in the
CSF blast cell count between the two
groups, and this varied widely. Fits were
uncommon as an associated feature and
were seen in one patient from both groups.
Although isolated CNS relapse (i.e. un-
associated with disease activity elsewhere)
was commoner in the non-T group (12 of
16 (75%) compared to 4 of 9 (44%); see
Table) this did not approach statistical
significance.
Considering the 3 parameters of T-cell
markers, CNS disease and diagnostic
WCC, their interdependence using a multi-
dimensional contingency table showed
that there was a strong relationship
between WCC and T-cell markers (P <
0.01) and between T-cell markers and
CNS disease (P < 0.02) but not between
c
0
cn cn
E
a)
cn
z
u
C
c
0
0
0.
0
0L
321J. S. LILLEYMAN AND P. J. SUGDEN
TABLE. Clinical features of CNS disease in T versus non-T ALL
Facial Hypotlhalamic
palsy syndrome
6 0
4 5
< 0-05 < 0-1-0 05
(x2) (x2)
CSF blast-cell
CouInt log mean
(X 1012/1)
2-27 + 0-27
2 38+02:3
NS
(t)
Months to C'NS
relapse from
(liagnosis
(mean)
5-6 + 14
18-2+ 2-2
<0-001
(f)
* i.e. No associate(l marrowN inifiltration at the time of CNS relapse.
white count and CNS disease (P=0.37).
This indicates that T ALL sufferers are
more likely to develop CNS disease
irrespective of their diagnostic WCC.
D)ISCUSSION
The overall incidence of CNS disease in
this sizeable group of patients is over
twice that seen in other recent studies
using early CNS prophylaxis (Aur et al.,
1978; Haghbin et al., 1980) but why this
should be so is not clear. As a consequence,
however, the relatively high frequency of
CNS involvement we have seen in the
non-T patients allows us an adequate
single-centre control group to compare
with the T ALLs, and to observe the
striking differences between them. It is
quite clear that T-cell patients not only
develop CNS disease more frequently, but
do so sooner and suffer facial-nerve palsies
more often. The reason may be, of course,
merely a reflection of a greater tumour
mass at diagnosis, and this would be sup-
ported by the clear association between
T ALL and high diagnostic WCC. It
would also follow the suggestion of an
earlier report (before the institution of
routine CNS prophylaxis) where the de-
velopment of meningeal disease was seen
to correlate with high leucocyte counts
and to inversely relate to platelet counts
(West et al., 1972).
It is possible, on the other hand, that
T-cell disease has a true predilection for
the CNS, and displays a genuine difference
in disease behaviour rather than non-
specific characteristics of any ALL variant
presenting at an advanced stage. There
are some indications from our findings that
this may be so. First, of our 9 T-cell
patients who developed CNS disease, 4
presented with less than 20 x 109/1 white
cells, and in the 8 who did not develop
CNS disease, 3 survived for over 6 months
(and so could have) but presented with
XVCC over 100 x 109/1. This apparent dis-
association of the white count and CNS
disease was confirmed for the group as a
whole (T and non-T) where it was seen
that, while there was a strong inter-
dependence between T-cell disease and a
high WCC (P < 0*01) and also betweeni
T-cell disease and CNS involvement
(P < 0*02) there was not between CNS
disease and WCC (P = 0 37).
Secondly, there are possibly some
clinical differences between T and non-T
CNS disease. Facial-nerve palsy seems to
be more common in T-cell patients, a fact
we have noted before (Lilleyman et al.,
1979) and conversely, it may be that hypo-
thalamic involvement is less common than
in non-T disease, where it seems to occur
as a later complication. These findings
would suggest a significant difference in
the migratory pattern of T and non-T
lymphoblasts, suggesting a greater bulk of
disease in santuary sites at the initiation
of therapy.
Although the explanation of our find-
ings is open to debate, the relevance ofthe
observations is depressingly clear. Prophy-
lactic therapy to the CNS, as currently
used, is ineffective in most patients with
T ALL. While it might be observed that
systemic therapy is equally ineffective
(Tsukimoto, 1976) the point is that an
improvement in one without a parallel
improvement in the other would not
brighten the prognosis for these uinfor-
tunate patients.
Total
17
8:3
T ALL
Noin-T ALL
P
Desvelope(d
CNS
relapse
9 (53%)
16 (19oo)
< 0-001
(logrank)
Isolate(d
CNS*
relapse
4
12
-NIS
(X2)
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